Last mentioned: Mar 6, 2026
Negotiated Prices Effective
New Medicare-negotiated prices for selected drugs are scheduled to take effect.
Market Breakout
Shares of AGL and DDOG skyrocket in high-volume trading sessions.
Expected Q4 Earnings Call
Management is anticipated to provide final 2025 figures and formal guidance for the 2026 fiscal year.
Price Cut Announcement
Novo Nordisk officially announces 50% list price reductions for semaglutide products.
Earnings Disclosure
agilon health files results of operations and financial condition with the SEC.
Earnings Preview Release
FinancialContent and other market trackers highlight ALHC as a key stock to watch ahead of Q4 reporting.
Baird Model Update
Analysts at Baird set a bullish $59 price target for ALHC, signaling high confidence in the tech-enabled MA model.
Material Agreement
agilon health enters into a new financial obligation and material agreement.
Senate Hearing
Novo Nordisk CEO Lars Fruergaard Jørgensen testifies before the Senate HELP Committee on high U.S. prices.
CMS Selection
Ozempic selected as one of the first 10 drugs for Medicare price negotiation.
Shares of agilon health (AGL) and Datadog (DDOG) experienced significant price appreciation on March 4, 2026, following a series of positive financial disclosures. The rally highlights a growing market confidence in value-based care models and the critical observability infrastructure required to scale them.
Inogen, Inc. reports a pivotal shift toward rental-based revenue and international expansion in its Q4 2025 earnings, while American Integrity Insurance Group emphasizes risk mitigation and financial stability. Together, these reports highlight a healthcare landscape balancing technological innovation with rigorous financial oversight.
Novo Nordisk has announced a landmark decision to reduce the list prices of its blockbuster GLP-1 medications, Ozempic and Wegovy, by up to 50%. The move follows intense regulatory scrutiny and the implementation of Medicare price negotiations under the Inflation Reduction Act.
Alignment Healthcare (ALHC) is set to report its fourth-quarter results, with investors focusing on membership growth and the medical loss ratio (MLR) within its tech-enabled Medicare Advantage platform. As the MA market faces regulatory headwinds, ALHC's ability to maintain clinical outcomes through its proprietary AVA software remains a critical differentiator.